Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Entsar Eladl

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood|March 4, 2021
Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?Entsar Eladl, Hong Chang
Blood|March 25, 2021
Multiple Auer rods in a mixed-phenotype acute leukemiaHong Chang, Entsar Eladl
Ejhaem|July 18, 2022
Mixed-phenotype acute leukemia with a predominant B/T and a small subset of myeloid lineage expressionMaryam Pourabdollah, Entsar Eladl, Aijun Liu, et al.
Journal of Hematology & Oncology|July 18, 2020
Role of CD47 in Hematological MalignanciesEntsar Eladl, Rosemarie Tremblay-LeMay, Nasrin Rastgoo, et al.
Leukemia Research|December 23, 2022
Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemiaQianghua Zhou, Davidson Zhao, Entsar Eladl, et al.
Cancer Medicine|November 17, 2022
Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequencyDavidson Zhao, Entsar Eladl, Mojgan Zarif, et al.
The Egyptian Journal of Immunology|January 3, 2019
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral TherapyNoha T Abou El-Khier, Dina Elhammady, Mona M Arafa, et al.
Leukemia Research|May 31, 2022
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1Davidson Zhao, Mojgan Zarif, Entsar Eladl, et al.
Diagnostics (Basel, Switzerland)|January 21, 2023
Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon AdenocarcinomaAfaf T Ibrahiem, Entsar Eladl, Eman A Toraih, et al.
Leukemia Research|September 10, 2023
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blastsDavidson Zhao, Qianghua Zhou, Mojgan Zarif, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood|March 4, 2021
Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?Entsar Eladl, Hong Chang
Blood|March 25, 2021
Multiple Auer rods in a mixed-phenotype acute leukemiaHong Chang, Entsar Eladl
Ejhaem|July 18, 2022
Mixed-phenotype acute leukemia with a predominant B/T and a small subset of myeloid lineage expressionMaryam Pourabdollah, Entsar Eladl, Aijun Liu, et al.
Journal of Hematology & Oncology|July 18, 2020
Role of CD47 in Hematological MalignanciesEntsar Eladl, Rosemarie Tremblay-LeMay, Nasrin Rastgoo, et al.
Leukemia Research|December 23, 2022
Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemiaQianghua Zhou, Davidson Zhao, Entsar Eladl, et al.
Cancer Medicine|November 17, 2022
Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequencyDavidson Zhao, Entsar Eladl, Mojgan Zarif, et al.
The Egyptian Journal of Immunology|January 3, 2019
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral TherapyNoha T Abou El-Khier, Dina Elhammady, Mona M Arafa, et al.
Leukemia Research|May 31, 2022
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1Davidson Zhao, Mojgan Zarif, Entsar Eladl, et al.
Diagnostics (Basel, Switzerland)|January 21, 2023
Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon AdenocarcinomaAfaf T Ibrahiem, Entsar Eladl, Eman A Toraih, et al.
Leukemia Research|September 10, 2023
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blastsDavidson Zhao, Qianghua Zhou, Mojgan Zarif, et al.
Pageof 1